---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-25-000083"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T12:54:00.460515+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aurinia announces positive Phase 1 results for aritinercept; robust Ig reductions support once-monthly dosing

## Summary
- Single doses of aritinercept (5-300 mg s.c.) well tolerated in 61 healthy subjects; no treatment-related Grade ≥3 AEs or SAEs.
- Mean immunoglobin reductions at Day 28: IgA up to 48%, IgM up to 55%, IgG up to 20%.
- Injection site reactions in 24% aritinercept vs 13% placebo; all Grade 1.
- Company plans to initiate clinical studies in at least two autoimmune diseases in H2 2025.
- Pharmacodynamic effects support once-monthly subcutaneous dosing.

## SEC filing metadata
- accession: 0001600620-25-000083
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000083/0001600620-25-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000083/auph-20250630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-25-000083
- JSON: https://secwatch.observer/filing/0001600620-25-000083.json
- Plain text: https://secwatch.observer/filing/0001600620-25-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.